GRANTS & Funding
TRI Foundation 2022 research grants
In 2022, the TRI Foundation is pleased to offer two grant schemes in breast cancer and kidney disease research. Both grant schemes are for early to mid-career TRI-based researchers and affiliated clinicians. Applications are now open for both until 5th September 2022. READ MORE
Linc Grant Scheme 2022
TRI, Metro South Health, Mater and Children's Health Queensland (Oncology Department) have joined together to offer the annual LINC grants, worth up to $50,000 each. These grants are aimed at fostering new collaborative research projects between TRI-based researchers and Mater, Metro South Health, Mater or Children's Health Queensland clinicians. FIND OUT MORE
TRI-CSIRO Grant Scheme 2022
TRI and the CSIRO Australian e-Health Research Centre are offering three $100,000 grants for collaborative research projects aimed at solving a healthcare challenge. All grant applications must involve a TRI-based researcher, CSIRO Australian e-Health Research Centre scientist and a TRI partner clinician (from either Metro South Health, Mater or Children's Health Queensland). Applications for the grants will open on Monday 8th August 2022. FIND OUT MORE
Requesting a Letter of support from TRI for Funding
If you are interested in applying for funding support from TRI please contact [email protected] for a link to the application form. Applications need to be made three weeks prior to the submission deadline for the relevant grant applications, and must include:
- What is novel about the proposal and what is its value-add as a TRI investment for the TRI community.
- Previous funding requests to TRI (successful or not) to the same or a different funding body.
- How the application meets each of the criteria against which it will be assessed by TRI.
- Support from the Institute Director at TRI of the primary applicant (CIA).
Read the full eligibility criteria and terms and conditions here
past FUNDING PROGRAMS AT TRI
Between 2015 and 2019. TRI ran the Spore and Drive grant schemes for translational research projects based at the institute. The aim was to support researchers progress their discoveries and translate their findings into the clinic. During the time the schemes run, TRI awarded $850,000 via 13 grants, with TRI’s partner institutions and industry collaborators matched this funding with a further $1,571,745.
|
Year awarded |
Grant scheme |
Principal Investigator |
Project title |
|
2015 |
Spore |
Dr Michelle Hill |
Obesity-induced Barrett’s oesophagus and associated cancer: mechanisms and diagnostic tools |
|
2015 |
Spore |
Dr Antje Blumenthal |
Towards biomarkers for patient stratification in sepsis |
|
2015 |
Spore |
Prof Rik Thompson |
Portable, single-sided MRI for routine, low-cost analysis of mammographic density |
|
2015 |
Spore |
Prof Ken O'Byrne |
Nucleoplasmin (NPM)1 a critical repair protein required for genomic stability |
|
2016 |
Spore |
A/Prof Jyotsna Batra |
Novel MicroRNA’s as potential targets for treating prostate cancer |
|
2016 |
Spore |
A/Prof Chamindie Punyadeera |
Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients for PD1 Therapy |
|
2018 |
Spore |
Prof Gerald Holtmann |
Modulation of the GI Microbiome with probiotics to treat constipation |
|
2018 |
Spore |
Prof John Hooper |
Theranostic biomolecules for improved diagnosis and treatment of pancreatic cancer |
|
2018 |
Spore |
Dr Arutha Kulasinghe |
Can liquid biopsy provide predictive biomarkers for checkpoint inhibitor response in Non-Small Cell Lung Cancer? |
|
2018 |
Spore |
Prof Peter Soyer |
Towards clinical diagnosis of inflammatory skin rashes using minimally‐invasive micro-sampling technologies |
|
2019 |
Spore |
A/Prof Jyotsna Batra |
Improving the PSA test to detect all lethal prostate cancers |
|
2019 |
Spore |
Prof Ben Panizza |
Therapeutic Potential for the Treatment of Adenoid Cystic Carcinoma (ACC) |
|
2019 |
Drive |
Prof Sandro Porceddu |
Durvax Trial: A Phase 1b, single centre, open label study of a therapeutic Human Papilomavirus (HPC) DNA vaccine co-administered with anti-PD-L1 immunotheraphy, Duravalumab (MED14736), for recurrent and/or metastatic HPV-related oropharnygeal cancer |
|
2021 |
LINC |
Dr Justine Gibson |
Dysbiosis as a long-term sequelae in patients that undergo treatment for tuberculosis |
|
2021 |
LINC |
Dr Sidharth Mantha |
Establishing a pipeline for rapid clinical translation of novel biomaterials for the treatment of brain cancer of metastatic origin |
|
2021 |
LINC |
A/Prof Erin McMeniman |
Determining Causative Mechanisms of Hidradenitis Suppurativa |
|
2021 |
LINC |
Dr Philip Rowell |
Elucidating the Role of Adipokine Axis Dysregulation in Bone Metastatic Cancer for the Strategic Positioning of New Therapeutic Agents |
|
2021 |
LINC |
Dr Timothy Edwards |
Making treatment-resistant schizophrenia more treatable: predicting life-threatening clozapine-induced-neutropenia using cellular genomics. |
|
2021 |
LINC |
Dr Yoon-Kyo An |
Identifying mechanism and new therapies to treat anaemia of inflammation in Inflammatory Bowel Diseases |
|
2021 |
LINC |
Dr Reuben Beer |
Linking Advanced Neuroimaging, Disease State and Clinical Measures in Multiple Sclerosis: A multi-disciplinary and multi-institutional research approach. |
|
2021 |
LINC |
Dr Jesrine Hong |
DNA methylation in circulating free fetal DNA: A potential biomarker to predict fetal growth restriction and severe perinatal outcomes? |
